Moomoo AI 已提取核心信息
Bristol-Myers Squibb Company, through its subsidiary Rudolph Merger Sub Inc., has announced an amendment to its tender offer to acquire all outstanding shares of RayzeBio, Inc. The offer, priced at $62.50 per share in cash, is detailed in an amended Schedule TO filed with the SEC on February 16, 2024. The amendment provides updated financial information, indicating that Bristol-Myers Squibb estimates a requirement of approximately $4.1 billion to complete the acquisition and related expenses. The company has confirmed the availability of sufficient funds to finance the acquisition, with $11.46 billion in cash and cash equivalents as of December 31, 2023. The funding sources include cash on hand, proceeds from a recent $13 billion Notes Offering, and potential short-term debt arrangements. The Notes Offering, completed on...Show More
Bristol-Myers Squibb Company, through its subsidiary Rudolph Merger Sub Inc., has announced an amendment to its tender offer to acquire all outstanding shares of RayzeBio, Inc. The offer, priced at $62.50 per share in cash, is detailed in an amended Schedule TO filed with the SEC on February 16, 2024. The amendment provides updated financial information, indicating that Bristol-Myers Squibb estimates a requirement of approximately $4.1 billion to complete the acquisition and related expenses. The company has confirmed the availability of sufficient funds to finance the acquisition, with $11.46 billion in cash and cash equivalents as of December 31, 2023. The funding sources include cash on hand, proceeds from a recent $13 billion Notes Offering, and potential short-term debt arrangements. The Notes Offering, completed on February 14, 2024, is not contingent upon the completion of the acquisition but includes mandatory redemption clauses for certain notes if the acquisition of Karuna Therapeutics, Inc. does not occur within a specified timeframe. The tender offer is not subject to any financing condition, and the amendment emphasizes that the financial condition of Bristol-Myers Squibb and its subsidiary is not relevant to shareholders' decisions regarding the tender offer.
百时美施贵宝公司通过其子公司Rudolph Merger Sub Inc. 宣布对收购RayzeBio, Inc.所有已发行股份的要约进行修订。该要约定价为每股现金62.50美元，详见2024年2月16日向美国证券交易委员会提交的经修订的附表TO。该修正案提供了最新的财务信息，表明百时美施贵宝估计需要约41亿美元才能完成收购和相关费用。该公司已确认有足够的资金为收购融资，截至2023年12月31日，现金及现金等价物为114.6亿美元。资金来源包括手头现金、最近130亿美元票据发行的收益以及潜在的短期债务安排。本次票据发行于2024年2月14日完成，不以收购完成为前提，但如果未在规定的时间范围内收购Karuna Therapeutics, Inc.，则包括某些票据的强制性赎回条款。本次要约不受任何融资条件的约束，该修正案强调百时美施贵宝及其子公司的财务状况与股东关于要约的决定无关。
百时美施贵宝公司通过其子公司Rudolph Merger Sub Inc. 宣布对收购RayzeBio, Inc.所有已发行股份的要约进行修订。该要约定价为每股现金62.50美元，详见2024年2月16日向美国证券交易委员会提交的经修订的附表TO。该修正案提供了最新的财务信息，表明百时美施贵宝估计需要约41亿美元才能完成收购和相关费用。该公司已确认有足够的资金为收购融资，截至2023年12月31日，现金及现金等价物为114.6亿美元。资金来源包括手头现金、最近130亿美元票据发行的收益以及潜在的短期债务安排。本次票据发行于2024年2月14日完成，不以收购完成为前提，但如果未在规定的时间范围内收购Karuna Therapeutics, Inc.，则包括某些票据的强制性赎回条款。本次要约不受任何融资条件的约束，该修正案强调百时美施贵宝及其子公司的财务状况与股东关于要约的决定无关。
有用
没用